Phase I study of echinomycin.
Echinomycin was administered to patients with advanced carcinoma in escalating doses ranging from 60 to 1500 micrograms/m2 given weekly by 15-minute iv infusions for four doses, with a subsequent 2-week rest period. Dose-limiting nausea, vomiting, and anorexia associated with varying degrees of renal and hepatic dysfunction proved dose-limiting at the 1500-micrograms/m2 level. Thrombocytopenia was noted in 15% of patients receiving greater than or equal to 700 micrograms/m2 and was severe in 11% without an evident dose-response relationship. Leukopenia was rare and mild when encountered. Allergic reactions were observed. Phase II trials are feasible using a dose schedule of 1200 micrograms/m2/week X 4 weeks.
Pazdur
R
R
Division of Hematology/Oncology, Wayne State University, Detroit, MI 48201.
Haas
C D
CD
Baker
L H
LH
Leichman
C G
CG
Decker
D
D
D002277:Carcinoma / Q000188:drug therapy*; D004448:Echinomycin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007364:Intercalating Agents / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use*
D007364:Intercalating Agents; D011810:Quinoxalines; D004448:Echinomycin